Which has higher valuation and earnings, INCY or CGON?

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.50 $1.29B $7.85 14.54 CG Oncology $4.04M 1,507.54 -$160.99M -$2.69 N/A

Is INCY or CGON more profitable?

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% CG Oncology -3,602.68% -25.20% -23.98%

Is BNTX or CGON more profitable?

BioNTech has a net margin of -63.54% compared to CG Oncology's net margin of -3,602.68%. BioNTech's return on equity of -6.86% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% CG Oncology -3,602.68% -25.20% -23.98%

Which has higher earnings and valuation, GMAB or CGON?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 6.46 $963M $1.27 30.30 CG Oncology $4.04M 1,507.54 -$160.99M -$2.69 N/A

Is GMAB or CGON more profitable?

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% CG Oncology -3,602.68% -25.20% -23.98%

Which has better earnings and valuation, EXEL or CGON?

Exelixis has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.28 $782.57M $3.18 18.51 CG Oncology $4.04M 1,507.54 -$160.99M -$2.69 N/A

Is EXEL or CGON more profitable?

Exelixis has a net margin of 35.33% compared to CG Oncology's net margin of -3,602.68%. Exelixis' return on equity of 42.17% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% CG Oncology -3,602.68% -25.20% -23.98%

CG Oncology (CGON) Competitors

$68.71 +1.33 (+1.97%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$68.56 -0.14 (-0.21%)

As of 04:37 AM Eastern

Compare

CGON vs. INCY, BNTX, GMAB, UTHR, and EXEL

Should you buy CG Oncology stock or one of its competitors? CG Oncology's main competitors and comparable companies include Incyte (INCY), BioNTech (BNTX), Genmab A/S (GMAB), United Therapeutics (UTHR), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CG Oncology compare to Incyte?

Incyte (NASDAQ:INCY) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Incyte has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Incyte presently has a consensus price target of $127.45, suggesting a potential upside of 11.67%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 27.75%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, Incyte had 16 more articles in the media than CG Oncology. MarketBeat recorded 16 mentions for Incyte and 0 mentions for CG Oncology. Incyte's average media sentiment score of 0.63 beat CG Oncology's score of 0.00 indicating that Incyte is being referred to more favorably in the media.

Company	Overall Sentiment
Incyte	Positive
CG Oncology	Neutral

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.50	$1.29B	$7.85	14.54
CG Oncology	$4.04M	1,507.54	-$160.99M	-$2.69	N/A

Summary

Incyte beats CG Oncology on 14 of the 17 factors compared between the two stocks.

How does CG Oncology compare to BioNTech?

BioNTech (NASDAQ:BNTX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

BioNTech has a net margin of -63.54% compared to CG Oncology's net margin of -3,602.68%. BioNTech's return on equity of -6.86% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, BioNTech had 15 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for BioNTech and 0 mentions for CG Oncology. BioNTech's average media sentiment score of 0.28 beat CG Oncology's score of 0.00 indicating that BioNTech is being referred to more favorably in the media.

Company	Overall Sentiment
BioNTech	Neutral
CG Oncology	Neutral

BioNTech has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

BioNTech currently has a consensus price target of $126.00, suggesting a potential upside of 29.05%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 27.75%. Given BioNTech's higher possible upside, equities research analysts plainly believe BioNTech is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

15.5% of BioNTech shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CG Oncology has lower revenue, but higher earnings than BioNTech. CG Oncology is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.61	-$1.29B	-$7.83	N/A
CG Oncology	$4.04M	1,507.54	-$160.99M	-$2.69	N/A

Summary

BioNTech beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Genmab A/S has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, Genmab A/S had 15 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for Genmab A/S and 0 mentions for CG Oncology. Genmab A/S's average media sentiment score of 0.35 beat CG Oncology's score of 0.00 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Genmab A/S	Neutral
CG Oncology	Neutral

Genmab A/S presently has a consensus target price of $40.83, suggesting a potential upside of 6.12%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 27.75%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	6.46	$963M	$1.27	30.30
CG Oncology	$4.04M	1,507.54	-$160.99M	-$2.69	N/A

Summary

Genmab A/S beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does CG Oncology compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

United Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.23	$1.33B	$27.95	19.19
CG Oncology	$4.04M	1,507.54	-$160.99M	-$2.69	N/A

United Therapeutics has a net margin of 41.56% compared to CG Oncology's net margin of -3,602.68%. United Therapeutics' return on equity of 20.18% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, United Therapeutics had 37 more articles in the media than CG Oncology. MarketBeat recorded 37 mentions for United Therapeutics and 0 mentions for CG Oncology. United Therapeutics' average media sentiment score of 0.37 beat CG Oncology's score of 0.00 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
United Therapeutics	Neutral
CG Oncology	Neutral

United Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

United Therapeutics presently has a consensus price target of $621.00, suggesting a potential upside of 15.77%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 27.75%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

United Therapeutics beats CG Oncology on 13 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Exelixis?

Exelixis (NASDAQ:EXEL) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Exelixis has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Exelixis has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.28	$782.57M	$3.18	18.51
CG Oncology	$4.04M	1,507.54	-$160.99M	-$2.69	N/A

85.3% of Exelixis shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Exelixis had 3 more articles in the media than CG Oncology. MarketBeat recorded 3 mentions for Exelixis and 0 mentions for CG Oncology. Exelixis' average media sentiment score of 0.69 beat CG Oncology's score of 0.00 indicating that Exelixis is being referred to more favorably in the media.

Company	Overall Sentiment
Exelixis	Positive
CG Oncology	Neutral

Exelixis has a net margin of 35.33% compared to CG Oncology's net margin of -3,602.68%. Exelixis' return on equity of 42.17% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Exelixis currently has a consensus target price of $50.29, suggesting a potential downside of 14.55%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 27.75%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Exelixis beats CG Oncology on 12 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.97B	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.36%
P/E Ratio	-25.54	12.99	274.34	26.20
Price / Sales	1,507.54	1,253.66	600.58	91.08
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	7.36	16.42	11.00	6.40
Net Income	-$160.99M	-$23.20M	$3.49B	$381.07M
7 Day Performance	-2.57%	-2.16%	-1.34%	-0.30%
1 Month Performance	-7.98%	-10.25%	-6.00%	-4.53%
1 Year Performance	80.20%	17.58%	7.30%	1.62%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.345 of 5 stars	$68.71 +2.0%	$87.78 +27.8%	+72.6%	$5.97B	$4.04M	N/A	142
INCY Incyte	3.994 of 5 stars	$123.20 -1.3%	$124.80 +1.3%	+31.4%	$24.97B	$5.14B	15.69	2,844	Analyst Forecast
BNTX BioNTech	3.8065 of 5 stars	$98.57 -0.5%	$126.00 +27.8%	-7.4%	$24.93B	$3.25B	N/A	7,807
GMAB Genmab A/S	3.9675 of 5 stars	$35.57 +0.6%	$39.50 +11.0%	+14.7%	$22.20B	$3.72B	28.01	3,119	News Coverage Analyst Forecast
UTHR United Therapeutics	3.9897 of 5 stars	$481.47 -0.8%	$621.00 +29.0%	+18.4%	$20.65B	$3.15B	17.23	1,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. INCY, BNTX, GMAB, UTHR, and EXEL

How does CG Oncology compare to Incyte?

Summary

How does CG Oncology compare to BioNTech?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to United Therapeutics?

Summary

How does CG Oncology compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. INCY, BNTX, GMAB, UTHR, and EXEL

How does CG Oncology compare to Incyte?

Do institutionals & insiders have more ownership in INCY or CGON?

Which has more risk & volatility, INCY or CGON?

Do analysts prefer INCY or CGON?

Is INCY or CGON more profitable?

Does the media prefer INCY or CGON?

Which has higher valuation and earnings, INCY or CGON?

Summary

How does CG Oncology compare to BioNTech?

Is BNTX or CGON more profitable?

Does the media refer more to BNTX or CGON?

Which has more volatility and risk, BNTX or CGON?

Do analysts recommend BNTX or CGON?

Do insiders & institutionals hold more shares of BNTX or CGON?

Which has higher valuation and earnings, BNTX or CGON?

Summary

How does CG Oncology compare to Genmab A/S?

Which has more volatility and risk, GMAB or CGON?

Is GMAB or CGON more profitable?

Does the media favor GMAB or CGON?

Do analysts prefer GMAB or CGON?

Do institutionals and insiders hold more shares of GMAB or CGON?

Which has higher earnings and valuation, GMAB or CGON?

Summary

How does CG Oncology compare to United Therapeutics?

Which has stronger valuation & earnings, UTHR or CGON?

Is UTHR or CGON more profitable?

Does the media refer more to UTHR or CGON?

Which has more risk and volatility, UTHR or CGON?

Do analysts recommend UTHR or CGON?

Do institutionals & insiders hold more shares of UTHR or CGON?

Summary

How does CG Oncology compare to Exelixis?

Which has more volatility and risk, EXEL or CGON?

Which has better earnings and valuation, EXEL or CGON?

Do insiders & institutionals hold more shares of EXEL or CGON?

Does the media prefer EXEL or CGON?

Is EXEL or CGON more profitable?

Do analysts recommend EXEL or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools